Patrick Chun

595 total citations
19 papers, 364 citations indexed

About

Patrick Chun is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Patrick Chun has authored 19 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Immunology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Patrick Chun's work include Immune cells in cancer (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and CAR-T cell therapy research (4 papers). Patrick Chun is often cited by papers focused on Immune cells in cancer (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and CAR-T cell therapy research (4 papers). Patrick Chun collaborates with scholars based in United States, Canada and France. Patrick Chun's co-authors include Mukesh K. Nyati, Theodore S. Lawrence, Mary A. Davis, Felix Y. Feng, Sooryanarayana Varambally, Carlos López, Zev A. Wainberg, Arul M. Chinnaiyan, Scott A. Tomlins and X. Li and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Patrick Chun

18 papers receiving 354 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrick Chun United States 9 243 142 101 73 47 19 364
M. D’Arcangelo Italy 12 200 0.8× 119 0.8× 196 1.9× 41 0.6× 16 0.3× 31 360
Susanne Beck Germany 8 123 0.5× 115 0.8× 47 0.5× 27 0.4× 40 0.9× 19 236
Antonio Gnoni Italy 7 162 0.7× 124 0.9× 76 0.8× 74 1.0× 24 0.5× 9 372
Mary Beard United States 9 265 1.1× 141 1.0× 111 1.1× 130 1.8× 13 0.3× 9 418
Varalakshmi Janamanchi United States 3 160 0.7× 273 1.9× 195 1.9× 26 0.4× 12 0.3× 5 498
Francesca Sparano Italy 9 219 0.9× 113 0.8× 103 1.0× 78 1.1× 5 0.1× 19 369
Yixin Liu China 9 173 0.7× 158 1.1× 46 0.5× 104 1.4× 7 0.1× 25 362
Simona Tortorella Italy 8 107 0.4× 185 1.3× 73 0.7× 57 0.8× 9 0.2× 12 334
Longwen Xu China 10 172 0.7× 185 1.3× 61 0.6× 81 1.1× 9 0.2× 24 361

Countries citing papers authored by Patrick Chun

Since Specialization
Citations

This map shows the geographic impact of Patrick Chun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Chun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Chun more than expected).

Fields of papers citing papers by Patrick Chun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Chun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Chun. The network helps show where Patrick Chun may publish in the future.

Co-authorship network of co-authors of Patrick Chun

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Chun. A scholar is included among the top collaborators of Patrick Chun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Chun. Patrick Chun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Chun, Patrick, et al.. (2021). AMV564 Depletes Myeloid-Derived Suppressor Cells and Expands T Cells: Potential to Address Key Limitations of Cellular Therapies. Blood. 138(Supplement 1). 1702–1702. 1 indexed citations
2.
Li, Mei, et al.. (2021). 849 ReSTORE T cell engager platform depletes MDSC in parallel with antigen-specific solid tumor cytotoxicity. SHILAP Revista de lepidopterología. A890–A890. 1 indexed citations
3.
Sarde, Aurélien, et al.. (2021). Abstract 528: MDSC suppress the T cell repertoire and contribute to a pathologic cytokine milieu in cancer patients. Cancer Research. 81(13_Supplement). 528–528. 3 indexed citations
4.
Mettu, Niharika B., Alexander Starodub, Sarina A. Piha‐Paul, et al.. (2021). Results of a phase 1 dose-escalation study of AMV564, a novel T-cell engager, alone and in combination with pembrolizumab in patients with relapsed/refractory solid tumors.. Journal of Clinical Oncology. 39(15_suppl). 2555–2555. 6 indexed citations
5.
Sarde, Aurélien, et al.. (2020). Selectivity of T Cell Engager AMV564 Against Different Leukemic Blast Populations and Potential Application for Patient Selection. Blood. 136(Supplement 1). 25–26. 3 indexed citations
6.
Piha‐Paul, Sarina A., Alexander Starodub, Michael Shafique, et al.. (2020). 372 Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the phase 1 solid tumor trial of AMV564, a novel T-cell engager. SHILAP Revista de lepidopterología. A226.2–A227. 2 indexed citations
7.
Starodub, Alexander, et al.. (2020). A phase I study to evaluate the T-cell engager AMV564 alone and in combination with pembrolizumab in subjects with advanced solid tumors.. Journal of Clinical Oncology. 38(15_suppl). 3101–3101. 2 indexed citations
8.
Westervelt, Peter, Jörge E. Cortes, Jessica K. Altman, et al.. (2019). Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood. 134(Supplement_1). 834–834. 49 indexed citations
9.
Shah, Manish A., Jean‐Philippe Metges, Patrick Chun, et al.. (2017). A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.. Journal of Clinical Oncology. 35(15_suppl). TPS4141–TPS4141. 5 indexed citations
10.
11.
Hodi, F. Stephen, Antoni Ribas, Adil Daud, et al.. (2014). Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.. Journal of Clinical Oncology. 32(15_suppl). 3006–3006. 34 indexed citations
12.
Hamid, Omid, Caroline Robert, Antoni Ribas, et al.. (2014). Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).. Journal of Clinical Oncology. 32(15_suppl). 3000–3000. 20 indexed citations
13.
Cherukuri, Durga, Tomo‐o Ishikawa, Patrick Chun, et al.. (2013). Targeted Cox2 gene deletion in intestinal epithelial cells decreases tumorigenesis in female, but not male, ApcMin/+ mice. Molecular Oncology. 8(2). 169–177. 18 indexed citations
14.
Padula, Gilbert D. A., et al.. (2010). Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer. Radiation Oncology. 5(1). 80–80. 4 indexed citations
15.
Chun, Patrick & Zev A. Wainberg. (2009). Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy.. PubMed. 3(5). 191–6. 17 indexed citations
16.
Feng, Felix Y., Carlos López, Daniel P. Normolle, et al.. (2007). Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivo. Clinical Cancer Research. 13(8). 2512–2518. 41 indexed citations
17.
Nyati, Mukesh K., Felix Y. Feng, Sooryanarayana Varambally, et al.. (2006). Ataxia Telangiectasia Mutated Down-regulates Phospho-Extracellular Signal-Regulated Kinase 1/2 via Activation of MKP-1 in Response to Radiation. Cancer Research. 66(24). 11554–11559. 25 indexed citations
18.
Chun, Patrick, et al.. (2006). Synergistic Effects of Gemcitabine and Gefitinib in the Treatment of Head and Neck Carcinoma. Cancer Research. 66(2). 981–988. 67 indexed citations
19.
Feng, Felix Y., Sooryanarayana Varambally, Scott A. Tomlins, et al.. (2006). Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene. 26(23). 3431–3439. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. D’Arcangelo Breakdown of academic impact, for papers by Susanne Beck Breakdown of academic impact, for papers by Antonio Gnoni Breakdown of academic impact, for papers by Mary Beard Breakdown of academic impact, for papers by Varalakshmi Janamanchi Breakdown of academic impact, for papers by Francesca Sparano Breakdown of academic impact, for papers by Yixin Liu Breakdown of academic impact, for papers by Simona Tortorella Breakdown of academic impact, for papers by Longwen Xu
Rankless by CCL
2026